drugset
drugset / Trial / NCT05673577

Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients

NCT05673577 ↗

Phase 2 Completed 41 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of camrelizumab in combination with cetuximab and chemotherapy as first-line for patients with relapsed/metastastic head and neck squamous cell carcinoma

Timeline

Start
2023-03-22
Primary completion
2025-06-30
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Other
Background Albumin paclitaxel Unknown 125 mg/m2 Other
Background Cetuximab Monoclonal antibody 500 mg/m2 Other
Background Cisplatin Other / unclassified 75 mg/m2 Other

Indications

head and neck squamous cell carcinoma